Download Free Advances Toward Improved Understanding And Treatment Of Uncommon Ovarian Cancer Types And Subtypes Book in PDF and EPUB Free Download. You can read online Advances Toward Improved Understanding And Treatment Of Uncommon Ovarian Cancer Types And Subtypes and write the review.

Ovarian cancer is an umbrella term for a collection of distinct disease entities (histotypes). Until now, the majority of research has focussed on the most common histotype, high-grade serous ovarian carcinoma (HGSOC), which accounts for 70% of cases. The less common histotypes – including endometrioid, clear cell, mucinous, low-grade serous, carcinosarcoma, and non-epithelial histotypes – have received far less research attention. Accordingly, while major advances in our understanding of HGSOC have led to molecularly-directed therapies that improve patient outcomes, progress in less common histotypes has lagged behind. Notably, many of the uncommon histotypes demonstrate resistance to conventional chemotherapy regimens, and their inherent biological differences suggest most are unlikely to respond to emerging molecular therapeutics designed to target the biology of common ovarian cancer types.
In an era of promising advances in cancer research, there are considerable and even alarming gaps in the fundamental knowledge and understanding of ovarian cancer. Researchers now know that ovarian cancer is not a single disease-several distinct subtypes exist with different origins, risk factors, genetic mutations, biological behaviors, and prognoses. However, persistent questions have impeded progress toward improving the prevention, early detection, treatment, and management of ovarian cancers. Failure to significantly improve morbidity and mortality during the past several decades is likely due to several factors, including the lack of research being performed by specific disease subtype, lack of definitive knowledge of the cell of origin and disease progression, and incomplete understanding of genetic and non-genetic risk factors. Ovarian Cancers examines the state of the science in ovarian cancer research, identifies key gaps in the evidence base and the challenges to addressing those gaps, considers opportunities for advancing ovarian cancer research, and examines avenues for translation and dissemination of new findings and communication of new information to patients and others. This study makes recommendations for public- and private-sector efforts that could facilitate progress in reducing the incidence of morbidity and mortality from ovarian cancers.
Ovarian cancer management is a rapidly changing field with new treatment agents available as a result of a greater understanding of the pathogenesis of this disease. In addition, both surgical and chemotherapeutic treatment strategies are evolving to maximise response in this disease. This book brings together leading specialists from around the world to discuss and outline a variety of new concepts in ovarian cancer, ranging from molecular biology and genetics through screening to both surgical and chemotherapeutic management.
New edition includes more than 350 new illustrations and 22 revised chapters Written by internationally recognized experts Each entry is structured the same way, from general to more specific information, which allows the reader to quickly access key information in every chapter Since the publication of the 1/e in 1977, Blaustein's Pathology of the Female Genital Tract has consolidated its position as the leading textbook of gynecological pathology. an essential reference for all pathologists and residents, this thoroughly updated Sixth Edition includes more than 1500 illustrations in color, i
This book comprehensively summarizes the biology, etiology, and pathology of ovarian cancer and explores the role of deep molecular and cellular profiling in the advancement of precision medicine. The initial chapter discusses our current understanding of the origin, development, progression and tumorigenesis of ovarian cancer. In turn, the book highlights the development of resistance, disease occurrence, and poor prognosis that are the hallmarks of ovarian cancer. The book then reviews the role of deep molecular and cellular profiling to overcome challenges that are associated with the treatment of ovarian cancer. It explores the use of genome-wide association analysis to identify genetic variants for the evaluation of ovarian carcinoma risk and prognostic prediction. Lastly, it highlights various diagnostic and prognostic ovarian cancer biomarkers for the development of molecular-targeted therapy.
The National Cancer Institute's (NCI) Clinical Trials Cooperative Group Program has played a key role in developing new and improved cancer therapies. However, the program is falling short of its potential, and the IOM recommends changes that aim to transform the Cooperative Group Program into a dynamic system that efficiently responds to emerging scientific knowledge; involves broad cooperation of stakeholders; and leverages evolving technologies to provide high-quality, practice-changing research.
Updated and expanded, the third edition of Surgery for Ovarian Cancer focuses on essential techniques for the effective management of ovarian cancer. It reflects the most contemporary science and surgical applications for the management of patients with ovarian cancer and related peritoneal surface malignancies. This new edition takes a step-by-step approach and includes new intraoperative photographs and videos illustrating surgical procedures. It is principally devoted to the technical aspects of cytoreductive surgery, with chapters divided according to anatomic region. The chapters cover relevant anatomical considerations, surgical challenges specific to each region, and operative approaches and techniques favored by the authors. The list of contributing authors has been expanded from the previous edition and includes international and world-renowned experts from the fields of gynecologic oncology and surgical oncology. The topics of minimally invasive surgery, secondary cytoreduction, palliative surgery, and postoperative care are also covered in detail. New to the third edition are chapters on preoperative risk stratification, regional therapeutics and peritonectomy procedures, and quality assurance relating to ovarian cancer surgery. This comprehensive text is essential reading for all practitioners working with patients with ovarian cancers.
The key aim of the proposed chapter is to provide readers a brief description for the most important parts of the field of circulating tumor cells (CTCs): the core techniques, including negative and positive selection-based CTC isolation, and the differences between them. Most importantly, we will also review the clinical applications and important findings in clinical trials. The evidence-based review will not only help clinicians use CTCs to predict recurrence and foresee the disease-related outcomes but also to inspire the researchers in this field to conduct further investigations.
In the last decade, research on cold atmospheric plasma (CAP) has significantly advanced our understanding of the effect of CAP on cancer cells and their potential for cancer treatment. This effect is due to the reactive oxygen and nitrogen species (RONS) created by plasma. This has been demonstrated for different cancer cell lines and the first clinical trials showed promising results. In addition, plasma could be combined with other treatments-such as immunotherapy-to boost its anticancer activity. The addition of new research tools to study the response of cancer cells to CAP-such as 3D in vitro, in ovo, and in vivo models and in silico approaches-as well as the use of -OMICS technologies could aid in unravelling the underlying mechanisms of CAP in cancer treatment. In order to progress towards widespread clinical application of CAP, an integrated study of the multidimensional effect of CAP in cancer treatment is essential. In this book, reviews and original research papers are published that provide new insights into the mechanisms of cold atmospheric plasma in cancer treatment, based on in vitro and in vivo experiments, clinical studies, as well as computer modeling.
This new volume updates the reader on selected areas of targeted therapy in breast cancer, with special emphasis on chemoprevention strategies, drug resistance, biomarkers, combination chemotherapy, angiogenesis inhibition and pharmacogenomics in the context of clinical efficacy. This selected review of targeted therapies will guide the reader on effective treatment as part of an integrated programme of patient management.